252 related articles for article (PubMed ID: 18607184)
1. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity.
Tsimikas S; Witztum JL
Curr Opin Lipidol; 2008 Aug; 19(4):369-77. PubMed ID: 18607184
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
3. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
[TBL] [Abstract][Full Text] [Related]
4. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
[TBL] [Abstract][Full Text] [Related]
5. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
[TBL] [Abstract][Full Text] [Related]
6. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
7. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
Tsimikas S; Tsironis LD; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2094-9. PubMed ID: 17626905
[TBL] [Abstract][Full Text] [Related]
8. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
9. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis).
Handa JT; Tagami M; Ebrahimi K; Leibundgut G; Janiak A; Witztum JL; Tsimikas S
Trans Am Ophthalmol Soc; 2015; 113():T5. PubMed ID: 26538774
[TBL] [Abstract][Full Text] [Related]
11. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
[TBL] [Abstract][Full Text] [Related]
12. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
[TBL] [Abstract][Full Text] [Related]
13. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.
Bergmark C; Dewan A; Orsoni A; Merki E; Miller ER; Shin MJ; Binder CJ; Hörkkö S; Krauss RM; Chapman MJ; Witztum JL; Tsimikas S
J Lipid Res; 2008 Oct; 49(10):2230-9. PubMed ID: 18594118
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) accelerates atherosclerosis in uremic mice.
Pedersen TX; McCormick SP; Tsimikas S; Bro S; Nielsen LB
J Lipid Res; 2010 Oct; 51(10):2967-75. PubMed ID: 20584868
[TBL] [Abstract][Full Text] [Related]
15. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.
Que X; Hung MY; Yeang C; Gonen A; Prohaska TA; Sun X; Diehl C; Määttä A; Gaddis DE; Bowden K; Pattison J; MacDonald JG; Ylä-Herttuala S; Mellon PL; Hedrick CC; Ley K; Miller YI; Glass CK; Peterson KL; Binder CJ; Tsimikas S; Witztum JL
Nature; 2018 Jun; 558(7709):301-306. PubMed ID: 29875409
[TBL] [Abstract][Full Text] [Related]
16. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.
Arai K; Luke MM; Koschinsky ML; Miller ER; Pullinger CR; Witztum JL; Kane JP; Tsimikas S
Atherosclerosis; 2010 Apr; 209(2):498-503. PubMed ID: 19880117
[TBL] [Abstract][Full Text] [Related]
17. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).
Yeang C; Hung MY; Byun YS; Clopton P; Yang X; Witztum JL; Tsimikas S
J Clin Lipidol; 2016; 10(3):594-603. PubMed ID: 27206947
[TBL] [Abstract][Full Text] [Related]
18. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
[TBL] [Abstract][Full Text] [Related]
19. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).
Tsimikas S; Duff GW; Berger PB; Rogus J; Huttner K; Clopton P; Brilakis E; Kornman KS; Witztum JL
J Am Coll Cardiol; 2014 May; 63(17):1724-34. PubMed ID: 24530664
[TBL] [Abstract][Full Text] [Related]
20. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases.
Trpkovic A; Resanovic I; Stanimirovic J; Radak D; Mousa SA; Cenic-Milosevic D; Jevremovic D; Isenovic ER
Crit Rev Clin Lab Sci; 2015; 52(2):70-85. PubMed ID: 25537066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
